Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

High-efficiency lentiviral transduction of primary human CD34(+) hematopoietic cells with low-dose viral inocula

Authors
Park, Sang WonPyo, Chul-WoongChoi, Sang-Yun
Issue Date
2월-2015
Publisher
SPRINGER
Keywords
CD34(+) bone marrow; Gene therapy; Hematopoietic cells; Progenitor cell assay; Pseudotyped lentiviral vector; Transduction efficiency; Viral inoculum
Citation
BIOTECHNOLOGY LETTERS, v.37, no.2, pp.281 - 288
Indexed
SCIE
SCOPUS
Journal Title
BIOTECHNOLOGY LETTERS
Volume
37
Number
2
Start Page
281
End Page
288
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/94491
DOI
10.1007/s10529-014-1678-z
ISSN
0141-5492
Abstract
Lentivirus-based vectors have the potential to transduce non-dividing primary stem cells. However, primary cells tend to be less susceptible to manipulation and require a high concentration of virus inoculum. Furthermore, increasing the concentration of the lentivirus inoculum may raise safety risks. Therefore, to develop a technique that allows high transduction efficiency at low multiplicities of infection (MOIs), we optimized a lentivirus-based system for cell lines and primary cells by determining the best condition using various parameters. When progenitor cell assays were conducted using human CD34(+) bone marrow and mononuclear cells, the transduction condition yielded a great number of eGFP(+) colonies with lower-dose viral inocula compared to that of current lentivirus-based transduction technologies. In conclusion, this system is anticipated to produce stable expression of a gene introduced into primary cells for preclinical studies with lower safety risks.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Life Sciences and Biotechnology > Division of Life Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE